Title: Clinical observation of Oxcarbazepine on the patients with epilepsy
Abstract: Objective To evaluate the efficacy,tolerability and safety(E-T-S) of Oxcarbazepine(OXC) on the patients with PS/SGTCS or GTCS.Methods 61 patients with PS/SGTCS or GTCS were divided into two groups.40 newly diagnosed patients who had never accepted standard therapy entered monotherapy group,and 21 patients who have had many AEDs in turn with poor efficacy served as add-on therapy group.In adults,the initial dose was 150 mg(given per night) and the maintenance dose was(600~2400) mg(given twice per day).In children,the initial dose was(4~5) mg/(kg·d) and the maintenance dose was(30~50) mg/(kg·d).With open-label auto-control method,we analyzed the E-T-S of the patients taking OXC during the first 24 weeks of treatment both in monothrapy group and add-on therapy group by nonparametic statistics.Results The total effective and effectual rates were 62.3% and 54.1%,respectively,with 49.2% of patients remaining seizure free and 24.6% of patients exiting,because of economic problem and/or adverse events exiting 12 patients.Six most common adverse events were dizziness,headache,somnolence,nausea, fatigue,and rash.For the most part,these adverse events tended to be transient.Conclusion The efficacy of OXC is sustained with good safety and tolerability profiles during the treatment of 24 weeks of patients with PS/SGTCS or GTCS.
Publication Year: 2005
Publication Date: 2005-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot